Manufacturer claims-data requirements depend on your entity type, products and dispensing channels. Use this guide to organize the requirements, deadlines and responsibilities that apply to your program.
What changed
The original manufacturer restriction model, launched in 2021, targeted contract-pharmacy claims only, submitted through the 340B ESP platform. That kept the burden on entities with contract-pharmacy networks. Beginning in 2024 and accelerating through 2026, several major manufacturers expanded their demands to all 340B dispenses. Including drugs dispensed from an entity-owned pharmacy and drugs administered in the clinic (buy-and-bill).
Manufacturers now operating under a universal-claims posture include Lilly, Novo Nordisk, AstraZeneca, Bristol Myers Squibb, and Amgen. Because these companies produce insulins, GLP-1s, and other high-volume products, few grantees can avoid at least one of them.
Who is affected
Applicability depends on the current manufacturer notice. Review the entity, product and dispensing scope for your program:
- Entities with no contract pharmacies that previously fell outside the model now have to submit data for in-house and clinic-administered claims.
- Small STD, Title X, and Ryan White clinics that dispense modest volumes are being asked for data they may never have compiled before.
- Multi-site entities face the burden across every registered site, multiplying the OPAIS and data-hygiene work.
Use the current manufacturer notice to confirm the applicable submission deadline for each policy.
The legal backdrop
Some states passed anti-restriction laws that carved out in-state entities, but those carve-outs are looking fragile. In April 2026, the Fourth Circuit struck down West Virginia's anti-restriction statute as likely preempted by federal law, signaling that state-level protections may not hold. Meanwhile, HRSA's voluntary rebate model, which would have shifted the mechanics again, was vacated by a federal court in February 2026, so the upfront-discount-plus-data model remains the reality for now.
What to do now
- Inventory every manufacturer you buy from and check each against the current restriction landscape. Our Manufacturer Policy Explorer filters this by entity type and dispensing model.
- Confirm your platform registrations in both 340B ESP and Truzo. Universal claims mean nothing if your submissions never arrive because you are not registered.
- Build a repeatable data-extraction process so 45-day windows are routine, not fire drills. This is a core piece of what program optimization and monthly internal audits maintain.
- Document eligibility rigorously. More data submitted means more surface area for a manufacturer or HRSA to question a claim. Clean patient-definition and eligibility records are your defense.
The bottom line
Universal claims mandates erase the old assumption that small, contract-pharmacy-free grantees are outside the manufacturer-restriction game. If you dispense any product from an affected manufacturer, you are in scope. The entities that stay whole will be the ones that treat data submission as a standing operational discipline. Not a scramble when a deadline lands.